These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 31765373)

  • 1. Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing.
    Chun YJ; Choi JW; Hong MH; Jung D; Son H; Cho EK; Min YJ; Kim SW; Park K; Lee SS; Kim S; Kim HR; Cho BC;
    PLoS One; 2019; 14(11):e0224379. PubMed ID: 31765373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2).
    Aisner DL; Sholl LM; Berry LD; Rossi MR; Chen H; Fujimoto J; Moreira AL; Ramalingam SS; Villaruz LC; Otterson GA; Haura E; Politi K; Glisson B; Cetnar J; Garon EB; Schiller J; Waqar SN; Sequist LV; Brahmer J; Shyr Y; Kugler K; Wistuba II; Johnson BE; Minna JD; Kris MG; Bunn PA; Kwiatkowski DJ;
    Clin Cancer Res; 2018 Mar; 24(5):1038-1047. PubMed ID: 29217530
    [No Abstract]   [Full Text] [Related]  

  • 3. Common driver mutations and smoking history affect tumor mutation burden in lung adenocarcinoma.
    Nagahashi M; Sato S; Yuza K; Shimada Y; Ichikawa H; Watanabe S; Takada K; Okamoto T; Okuda S; Lyle S; Takabe K; Tsuchida M; Wakai T
    J Surg Res; 2018 Oct; 230():181-185. PubMed ID: 30072189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
    Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world utility of next-generation sequencing for targeted gene analysis and its application to treatment in lung adenocarcinoma.
    Kim JH; Yoon S; Lee DH; Jang SJ; Chun SM; Kim SW
    Cancer Med; 2021 May; 10(10):3197-3204. PubMed ID: 33960703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
    Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
    Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of tumour mutational burden in resected stage I and II lung adenocarcinomas from a European Thoracic Oncology Platform Lungscape cohort.
    Bubendorf L; Zoche M; Dafni U; Rüschoff JH; Prince SS; Marti N; Stavrou A; Kammler R; Finn SP; Moch H; Peters S; Stahel RA
    Lung Cancer; 2022 Dec; 174():27-35. PubMed ID: 36283211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical relevance of somatic mutations in Chinese lung adenocarcinoma and their prognostic implications for survival.
    Li T; Liu J; Zhou Y; Huang S; Wang D; Chen J; Fu Y; He P
    Cancer Med; 2024 May; 13(10):e7227. PubMed ID: 38770632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Precision medicine in age-specific non-small-cell-lung-cancer patients: Integrating biomolecular results into clinical practice-A new approach to improve personalized translational research.
    Vavalà T; Monica V; Lo Iacono M; Mele T; Busso S; Righi L; Papotti M; Scagliotti GV; Novello S
    Lung Cancer; 2017 May; 107():84-90. PubMed ID: 27346245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.
    Kadara H; Choi M; Zhang J; Parra ER; Rodriguez-Canales J; Gaffney SG; Zhao Z; Behrens C; Fujimoto J; Chow C; Yoo Y; Kalhor N; Moran C; Rimm D; Swisher S; Gibbons DL; Heymach J; Kaftan E; Townsend JP; Lynch TJ; Schlessinger J; Lee J; Lifton RP; Wistuba II; Herbst RS
    Ann Oncol; 2017 Jan; 28(1):75-82. PubMed ID: 27687306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency and clinical significance of NF1 mutation in lung adenocarcinomas from East Asian patients.
    Pan Y; Yuan C; Cheng C; Zhang Y; Ma Y; Zheng D; Zheng S; Li Y; Jin Y; Sun Y; Chen H
    Int J Cancer; 2019 Jan; 144(2):290-296. PubMed ID: 30230541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hot spot mutations in Finnish non-small cell lung cancers.
    Mäki-Nevala S; Sarhadi VK; Rönty M; Kettunen E; Husgafvel-Pursiainen K; Wolff H; Knuuttila A; Knuutila S
    Lung Cancer; 2016 Sep; 99():102-10. PubMed ID: 27565922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma.
    Bria E; Pilotto S; Amato E; Fassan M; Novello S; Peretti U; Vavalà T; Kinspergher S; Righi L; Santo A; Brunelli M; Corbo V; Giglioli E; Sperduti I; Milella M; Chilosi M; Scarpa A; Tortora G
    Oncotarget; 2015 May; 6(14):12783-95. PubMed ID: 25904052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of genomic alterations of lung adenocarcinoma in young never-smokers.
    Luo W; Tian P; Wang Y; Xu H; Chen L; Tang C; Shu Y; Zhang S; Wang Z; Zhang J; Zhang L; Jiang L; Liu L; Che G; Guo C; Zhang H; Wang J; Li W
    Int J Cancer; 2018 Oct; 143(7):1696-1705. PubMed ID: 29667179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
    Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
    Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spectrum of gene mutations detected by next generation exome sequencing in brain metastases of lung adenocarcinoma.
    Preusser M; Berghoff AS; Koller R; Zielinski CC; Hainfellner JA; Liebmann-Reindl S; Popitsch N; Geier CB; Streubel B; Birner P
    Eur J Cancer; 2015 Sep; 51(13):1803-11. PubMed ID: 26164066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decoding tumor mutation burden and driver mutations in early stage lung adenocarcinoma using CT-based radiomics signature.
    Wang X; Kong C; Xu W; Yang S; Shi D; Zhang J; Du M; Wang S; Bai Y; Zhang T; Chen Z; Ma Z; Wang J; Dong G; Sun M; Yin R; Chen F
    Thorac Cancer; 2019 Oct; 10(10):1904-1912. PubMed ID: 31414580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a small mutation panel of coding sequences to predict the efficacy of immunotherapy for lung adenocarcinoma.
    Li Y; Jiang W; Li T; Li M; Li X; Zhang Z; Zhang S; Liu Y; Zhao W; Gu Y; Qi L; Ao L; Guo Z
    J Transl Med; 2020 Jan; 18(1):25. PubMed ID: 31937321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequently used quantitative polymerase chain reaction-based methods overlook potential clinically relevant genetic alterations in epidermal growth factor receptor compared with next-generation sequencing: a retrospective clinical comparison of 1839 lung adenocarcinomas.
    Tønnesen E; Lade-Keller J; Stougaard M
    Hum Pathol; 2021 Sep; 115():67-75. PubMed ID: 34153308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.